PROGENIKA BIOPHARMA, S.A. Patent applications |
Patent application number | Title | Published |
20160060696 | METHOD FOR THE IDENTIFICATION BY MOLECULAR TECHNIQUES OF GENETIC VARIANTS THAT ENCODE NO D ANTIGEN (D-) AND ALTERED C ANTIGEN (C+W) - The invention relates to genotyping and blood cell antigen determination. In particular, the invention addresses discriminating the RHD*DIIIa-CE(4-7)-D or RHD*DIIIa-CE(4-7)-D)-like blood type variants, from RHD*DIIIa, RHD*DIVa-2 and other blood type variants. The invention provides methods for genotyping a subject, comprising determining at least 4 markers in a sample that has been obtained from the subject, wherein the markers comprise:
| 03-03-2016 |
20160032386 | GENETIC MARKERS FOR OSTEOARTHRITIS - A method for predicting the severity or progression of OA in a human subject, comprising: determining the identity of at least one allele at each of at least 4 positions of single nucleotide polymorphism (SNPs) selected from the group consisting of: rs2206593, rs10465850, rs780094, rs1374281, rs1143634, rs2073508, rs2243250, rs4720262, rs917760, rs7838918, rs12009, rs730720, rs874692, rs893953, rs1799750, rs10845493, rs11054704, rs7986347, rs1802536, rs10519263, rs7342880, rs16947882 and rs10413815, and one or more SNPs in linkage disequilibrium at a level of at least R | 02-04-2016 |
20150376708 | PROBES AND METHODS FOR DETERMINING THE PRESENCE OR ABSENCE OF GENETIC SEGMENTS - A method for determining the presence or absence of a genetic segment of interest, such as an exon, an intron or a promoter, in a DNA-containing sample, and probe sets for use in such methods, including probe sets comprising oligonucleotide probes having nucleotides sequences selected from those of SEQ ID NOS: 1-101. | 12-31-2015 |
20140255923 | DISCRIMINATION OF BLOOD TYPE VARIANTS - The present invention provides a method for detecting the presence or absence of, or for discriminating between, blood type variants, including RHD*r′s, RHD*DIIIa and RHD*DIVa-2. The method comprises amplifying by PCR a sample obtained from a human subject at intron 3 of the RHD gene locus. The invention also provides products, in particular, probes, primers and kits for use in the method of the invention. | 09-11-2014 |
20140220567 | DISCRIMINATION OF BLOOD TYPE VARIANTS - The present invention provides a method for detecting the presence or absence of, or for discriminating between, blood type variants, including RHD*r′s, RHD*DIIIa, RHD*DIVa-2, RHCE*cs | 08-07-2014 |
20130263294 | MARKERS FOR JOINT DISPLASIA, OSTEOARTHRITIS AND CONDITIONS SECONDARY THERETO - A method for predicting risk of joint dysplasia, osteoarthritis and/or a condition that is secondary to joint dysplasia in a mammalian subject of the order Carnivora, the method comprising: (a) determining the genotype of said subject in respect of one or more genetic polymorphisms and/or alterations, such as polymorphisms in the CHST3 gene; and (b) providing a prediction of said risk based on said genotype. Products for use in such a method and related methods of determining propensity of a subject to respond to therapy and of selective breeding, are also disclosed. | 10-03-2013 |
20130184167 | GENETIC MARKERS FOR THE PROGNOSIS OF MULTIPLE SCLEROSIS - The present invention relates to a series of genes the expression of which is altered in subjects suffering multiple sclerosis with respect to healthy subjects or in subjects suffering multiple sclerosis with a good prognosis with respect to subjects suffering multiple sclerosis with a bad prognosis. A subset formed by 13 genes and two clinical variables which allows predicting the progress of a patient with a high reliability has been validated from an initial set of genes which showed said differential expression. From said expression values, the invention provides methods for predicting the progress of a patient diagnosed with multiple sclerosis from tables of conditional probability between the expression levels of a determined gene or group of genes and the probability that the patient has a good or bad prognosis of the disease. | 07-18-2013 |
20110098191 | IN VITRO METHODS FOR DETECTING RENAL CANCER - The present invention refers to an in vitro method for detecting the presence of renal cancer in an individual, for determining the stage, malignancy or severity of said carcinoma in the individual or for monitoring the effect of the therapy administered to an individual having said cancer; to the search, identification, development and assessment of the efficacy of compounds for therapy for said cancer in an attempt to develop new drugs; as well as to agents inducing Plexin-131 protein expression and/or activity, or to agents inhibiting the effects of Plexin-B1 protein expression and/or activity repression. | 04-28-2011 |
20110045997 | METHOD AND PRODUCT FOR "IN VITRO" GENOTYPING WITH APPLICATIONS IN ANTI-AGEING MEDICINE - The invention relates to an “in vitro” method for determining the global genetic risk a subject has of developing a pathology associated with aging. Said method is based on the combination of particular genetic risks of developing common pathologies associated with aging. Said particular genetic risks are determined from the results obtained from the simultaneous genotyping of certain genetic variations associated with said pathologies associated with aging and the main objective of which is the use thereof in anti-aging medicine. | 02-24-2011 |
20100068710 | METHODS AND PRODUCTS FOR IN VITRO GENOTYPING - An in vitro method for genotyping genetic variations in an individual, and products for use in the method. | 03-18-2010 |
20080274968 | IN VITRO METHODS FOR DETECTING RENAL CANCER - The present invention refers to an in vitro method for detecting the presence of renal cancer in an individual, for determining the stage, malignancy or severity of said carcinoma in the individual or for monitoring the effect of the therapy administered to an individual having said cancer; to the search, identification, development and assessment of the efficacy of compounds for therapy for said cancer in an attempt to develop new drugs; as well as to agents inducing Plexin-131 protein expression and/or activity, or to agents inhibiting the effects of Plexin-B1 protein expression and/or activity repression. | 11-06-2008 |